Although the first phase 3 trial of anifrolumab did not meet its primary end point, other study end points that were met suggested a clinical benefit for the monoclonal antibody in systemic lupus erythematosus.
Dr Jeffrey Curtis discusses the web-based survey that identified unmet needs perceived by patients with rheumatoid arthritis.
Researchers investigated the protein expression of interleukin (IL)-41 in the synovial tissue of patients with psoriatic arthritis, rheumatoid arthritis, and osteoarthritis and evaluated the production of IL-41 from the enthesis.
Researchers assessed the attainability and effect of the Definitions of Remission in Systemic Lupus Erythematosus (SLE) compared with the lupus low disease activity state in patients with SLE.
Researchers investigated the association between exposure to urate-lowering drugs and the progression and recovery of chronic kidney disease in patients with gout.
Researchers investigated the effects of canagliflozin on serum urate levels and gout in patients with type 2 diabetes.
Dr Costenbader talks about the contributions made by the Lupus Foundation of America, the barriers affecting outcomes in lupus, and the current state of diagnostic tools and treatments for the disease.
Researchers investigated the long-term safety and effectiveness of peficitinib in the treatment of rheumatoid arthritis.
In a post hoc analysis of the ASTRAEA study, researchers evaluated the effect of BMI on subsequent response to abatacept in psoriatic arthritis.
The study identified biomarkers for changes in bone mineral density at three anatomic sites in patients with osteoporosis secondary to RA.
